61MA Stock Overview
A private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, buyout. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
61MA passed our risk checks.
MedCap AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 46.45 |
| 52 Week High | SEK 52.60 |
| 52 Week Low | SEK 25.95 |
| Beta | 0.70 |
| 11 Month Change | 7.90% |
| 3 Month Change | -2.52% |
| 1 Year Change | 74.30% |
| 33 Year Change | 181.86% |
| 5 Year Change | n/a |
| Change since IPO | 139.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 61MA | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 3.5% | 2.2% | 0.2% |
| 1Y | 74.3% | 3.6% | 8.5% |
Return vs Industry: 61MA exceeded the German Life Sciences industry which returned 3.6% over the past year.
Return vs Market: 61MA exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 61MA volatility | |
|---|---|
| 61MA Average Weekly Movement | 5.9% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 61MA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 61MA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 534 | Anders Dahlberg | medcap.se/en/ |
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, pharmaceuticals, med tech and assistive tech companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Nordic region and Northern Europe.
MedCap AB (publ) Fundamentals Summary
| 61MA fundamental statistics | |
|---|---|
| Market cap | €724.93m |
| Earnings (TTM) | €19.83m |
| Revenue (TTM) | €156.65m |
36.6x
P/E Ratio4.6x
P/S RatioIs 61MA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 61MA income statement (TTM) | |
|---|---|
| Revenue | SEK 1.80b |
| Cost of Revenue | SEK 734.60m |
| Gross Profit | SEK 1.07b |
| Other Expenses | SEK 838.90m |
| Earnings | SEK 228.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | 15.40 |
| Gross Margin | 59.22% |
| Net Profit Margin | 12.66% |
| Debt/Equity Ratio | 6.3% |
How did 61MA perform over the long term?
See historical performance and comparison